Targeted Lentiviral Delivery Without Vector Reengineering
Rather than requiring genetic modification of the viral glycoprotein, G-Link uses a modular protein adaptor to blind native VSV-G tropism and redirect delivery after vector production. The post Targeted Lentiviral Delivery Without Vector Reengineering appeared first on GEN - Genetic Engineering and Biotechnology News .
VSV-G is the surface glycoprotein of the vesicular stomatitis virus. Lentiviral vectors utilizing VSV-G have broad tropism, substantial cargo capacity, and are easy to produce. Targeted delivery traditionally required modifying the viral glycoprotein. Vyriad's G-Link targeting platform offers a different approach. G-Link uses a modular protein adaptor to mask VSV-G's native tropism and redirect delivery post-production, without genetic modification of the glycoprotein.
The adaptor comprises a Cysteine-rich domain from low-density lipoprotein receptor, a trimerizing peptide to complement VSV-G's trimeric structure, and a CD3-targeting moiety for T-cell specificity. The architecture maintains binding under physiological calcium concentrations but is reversible at low-calcium conditions, allowing entry into endosomal environments.
In preclinical studies, G-Link-capped lentiviral vectors delivering a BCMA CAR in a mouse model of multiple myeloma produced complete tumor clearance without toxicity. The platform can simplify T-cell engineering ex vivo and enable targeted T-cell delivery in vivo through post-production mixing. G-Link is available for research use only, with free evaluations offered to qualified researchers.
Written by urgent.news from GEN Biotechnology's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
